Myelodysplastic Syndrome Podcasts Myelodysplastic Syndrome RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Preventing Kidney Injury From Coronary Angiography, Decreasing Musculoskeletal Diagnostic Imaging, Review of Myelodysplastic Syndromes, and more
Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the September 6, 2022 issue. (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - September 6, 2022 Category: General Medicine Authors: JAMA Network Source Type: podcasts

How to Manage MDS Patients who are Ineligible for Transplant
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on how myelodysplastic syndrome (MDS) patients who are ineligible for transplants can be managed. <br /> Author: obr Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2019 Category: Cancer & Oncology Source Type: podcasts

Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials
Aref Al-Kali MD Of The Mayo Clinic Discusses Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials. Author: Annual-Meeting Added: 06/12/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2019 Category: Cancer & Oncology Source Type: podcasts

Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning
Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018 Author: ASHReport Added: 12/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 14, 2018 Category: Cancer & Oncology Source Type: podcasts

Personalized Model for Allogeneic Hematopoietic Stem Cell Patients with Myelodysplastic Syndromes
Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplast... Author: ASHReport Added: 12/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 14, 2018 Category: Cancer & Oncology Source Type: podcasts

Molecular background studies to aid diagnosis and treatment of MDS
With the the field of molecular diagnostics rapidly advancing, the demand for prognostic and diagnostic molecular information on myelodysplastic syndrome (MDS) is also increasing. Here, Torsten Haferl... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Identifying genetic mutations for diagnosing MDS
Knowledge of the molecular background of myelodysplastic syndrome (MDS) has been greatly advanced by developments in techniques such as next-generation sequencing (NGS) and ChIP-sequencing. Professor ... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

The role of EZH2 mutations in MDS
EZH2 mutations are associated with a poor prognosis in myelodysplastic syndromes (MDS). In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rashmi... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Is there hope for treating TP53-mutated MDS?
In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic syndromes (MDS) and the results of the Phase Ib/II cl... Author: VJHemOnc Added: 08/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Hypomethylating agents for low risk MDS
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients with high risk myelodysplastic syndromes (MDS) to individ... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

IDH inhibitors for AML and MDS
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Bu... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

A new set of treatment options for low-risk MDS
Treatments for low-risk myelodysplastic syndromes (MDS) cannot cure the disease, but rather aim to improve quality of life, reduce complications and increase overall survival by reducing cytopenia. In... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

A worldwide Phase III trial treating AML with pracinostat
Pracinostat has been shown to be an effective therapy for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in several Phase I and Phase II studies. Here, Guillermo Garcia-Mane... Author: VJHemOnc Added: 07/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2018 Category: Cancer & Oncology Source Type: podcasts

Update MDS and Nonmalignant Heme
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about updates on Myelodysplastic syndrome and nonmalignant hemetology at MOASCs Spotlight On Hematology in Huntington Beach. <br /> Author: moasc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 2, 2018 Category: Cancer & Oncology Source Type: podcasts

Highlights from MDS and Nonmalignant Hematology - New drugs for MDS: Rigosertib, Luspatercept, Ibrutnib
Kanwarpal Kahlon, MD, from Ronald Reagan UCLA Medical Center talks about the highlights from Myelodysplastic Syndrome (MDS) and nonmalignant hematology and also new drugs for MDS: Rigosertib, Luspater... Author: moasc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2018 Category: Cancer & Oncology Source Type: podcasts